Dynavax Technologies (NASDAQ:DVAX) Given “Buy” Rating at William Blair

Dynavax Technologies (NASDAQ:DVAX)‘s stock had its “buy” rating restated by equities research analysts at William Blair in a report issued on Friday, June 21st, Stock Target Advisor reports. William Blair also issued estimates for Dynavax Technologies’ Q2 2019 earnings at ($0.64) EPS, Q3 2019 earnings at ($0.52) EPS, Q4 2019 earnings at ($0.37) EPS, FY2019 earnings at ($2.16) EPS, Q1 2020 earnings at ($0.36) EPS, Q2 2020 earnings at ($0.32) EPS, Q3 2020 earnings at ($0.31) EPS, Q4 2020 earnings at ($0.28) EPS and FY2020 earnings at ($1.28) EPS.

A number of other equities analysts have also commented on DVAX. BidaskClub lowered Virtu Financial from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 12th. Zacks Investment Research upgraded Gerdau from a “sell” rating to a “hold” rating in a research note on Monday, May 13th. Royal Bank of Canada reiterated a “buy” rating on shares of PrairieSky Royalty in a research note on Friday, May 24th. Cantor Fitzgerald set a $85.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, February 26th. Finally, ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $16.81.

DVAX traded up $0.25 during trading on Friday, reaching $4.03. 1,988,436 shares of the stock traded hands, compared to its average volume of 1,546,087. Dynavax Technologies has a fifty-two week low of $3.57 and a fifty-two week high of $16.15. The firm’s 50-day moving average price is $4.25. The company has a debt-to-equity ratio of 4.88, a quick ratio of 4.61 and a current ratio of 5.27. The stock has a market cap of $262.21 million, a PE ratio of -1.58 and a beta of 0.67.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.05. Dynavax Technologies had a negative return on equity of 190.84% and a negative net margin of 1,156.11%. The company had revenue of $5.77 million for the quarter, compared to analyst estimates of $5.95 million. During the same period last year, the company earned ($0.63) earnings per share. The business’s revenue was up 3294.1% compared to the same quarter last year. On average, equities research analysts expect that Dynavax Technologies will post -2.13 EPS for the current year.

In other Dynavax Technologies news, SVP Robert Coffman sold 32,218 shares of Dynavax Technologies stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $4.58, for a total transaction of $147,558.44. Following the sale, the senior vice president now directly owns 132,470 shares of the company’s stock, valued at $606,712.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.90% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in DVAX. Chicago Capital LLC boosted its position in shares of Dynavax Technologies by 15.5% during the 2nd quarter. Chicago Capital LLC now owns 2,937,266 shares of the biopharmaceutical company’s stock worth $11,720,000 after acquiring an additional 393,124 shares in the last quarter. Clearbridge Investments LLC boosted its position in shares of Dynavax Technologies by 3.4% during the 1st quarter. Clearbridge Investments LLC now owns 1,161,338 shares of the biopharmaceutical company’s stock worth $8,489,000 after acquiring an additional 38,400 shares in the last quarter. Marshall Wace North America L.P. acquired a new stake in shares of Dynavax Technologies during the 1st quarter worth approximately $1,468,000. Marshall Wace LLP boosted its position in shares of Dynavax Technologies by 225.0% during the 1st quarter. Marshall Wace LLP now owns 16,449 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 11,387 shares in the last quarter. Finally, Edmond DE Rothschild Holding S.A. boosted its position in shares of Dynavax Technologies by 14.1% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 590,700 shares of the biopharmaceutical company’s stock worth $4,318,000 after acquiring an additional 72,900 shares in the last quarter. 81.94% of the stock is currently owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Further Reading: Economic Reports

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.